Technical Analysis for SNGX - Soligenix, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 3.86 | 5.18% | 0.19 |
SNGX closed up 5.18 percent on Friday, November 1, 2024, on 49 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
Earnings due: Nov 11
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 0.00% | |
| Crossed Above 50 DMA | Bullish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| 20 DMA Resistance | Bearish | 5.18% | |
| 50 DMA Resistance | Bearish | 5.18% | |
| Bollinger Band Squeeze | Range Contraction | 5.18% | |
| Outside Day | Range Expansion | 5.18% | |
| Down 3 Days in a Row | Weakness | 5.18% | |
| Bollinger Band Squeeze | Range Contraction | 3.49% | |
| NR7 | Range Contraction | 3.49% |
| Alert | Time |
|---|---|
| Rose Above 10 DMA | about 17 hours ago |
| Possible Inside Day | about 17 hours ago |
| 10 DMA Resistance | about 20 hours ago |
| Down 1% | about 20 hours ago |
| Up 2% | about 20 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/11/2024
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases where, as well as developing several biodefense vaccines and therapeutics. The Company operates in two reportable segments: BioTherapeutics and BioDefense. The BioTherapeutics business segment intends to develop orBec ' (oral beclomethasone dipropionate, or oral BDP) and other biotherapeutic products, including LPM TM Leuprolide. The BioDefense business segment intends to convert its ricin toxin vaccine and radiation injury programs from early stage development to advanced development and manufacturing. Soligenix, Inc, formerly known as DOR BioPharma, Inc, is headquartered in Princeton, New Jersey.
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Cancer Treatment Gastrointestinal Radiation Therapeutic Products Toxins Biodefense Proteins Biological Warfare Gastrointestinal Disease Lectins Biotherapeutic Products
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Cancer Treatment Gastrointestinal Radiation Therapeutic Products Toxins Biodefense Proteins Biological Warfare Gastrointestinal Disease Lectins Biotherapeutic Products
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 32.0 |
| 52 Week Low | 1.8301 |
| Average Volume | 138,992 |
| 200-Day Moving Average | 6.27 |
| 50-Day Moving Average | 3.79 |
| 20-Day Moving Average | 3.79 |
| 10-Day Moving Average | 3.75 |
| Average True Range | 0.29 |
| RSI (14) | 51.22 |
| ADX | 29.38 |
| +DI | 21.45 |
| -DI | 13.19 |
| Chandelier Exit (Long, 3 ATRs) | 3.57 |
| Chandelier Exit (Short, 3 ATRs) | 4.38 |
| Upper Bollinger Bands | 4.17 |
| Lower Bollinger Band | 3.41 |
| Percent B (%b) | 0.59 |
| BandWidth | 19.94 |
| MACD Line | -0.02 |
| MACD Signal Line | -0.03 |
| MACD Histogram | 0.0086 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.22 | ||||
| Resistance 3 (R3) | 4.18 | 4.02 | 4.16 | ||
| Resistance 2 (R2) | 4.02 | 3.93 | 4.04 | 4.14 | |
| Resistance 1 (R1) | 3.94 | 3.87 | 3.98 | 3.98 | 4.12 |
| Pivot Point | 3.78 | 3.78 | 3.80 | 3.80 | 3.78 |
| Support 1 (S1) | 3.70 | 3.69 | 3.74 | 3.74 | 3.60 |
| Support 2 (S2) | 3.54 | 3.63 | 3.56 | 3.58 | |
| Support 3 (S3) | 3.46 | 3.54 | 3.56 | ||
| Support 4 (S4) | 3.50 |
